Tools, Diagnostics & CDMO

CellCarta has established a strategic partnership with Waters Corporation to jointly pursue companion diagnostic and next-generation flow cytometry opportunities with pharmaceutical and biotechnology companies. The collaboration will initially emphasize flow cytometry-based programs, aiming to give sponsors a coordinated path from biomarker strategy through clinical development, regulatory submission and global commercialization. Waters will provide underlying technology capabilities including instrumentation, reagents, standardized panels, assay development, software analysis, and where appropriate custom reagent and IVD commercialization, while CellCarta will integrate and deploy assays across its global CDx Lab Network, supporting Phase I-III clinical trial testing, analytical and clinical evidence generation, regulatory and logistics support, and commercial laboratory services. The companies cited existing platform alignment between CellCarta's CAP-accredited laboratory in Jining, China and BD flow cytometry platforms as a practical foundation for global sponsors seeking to include China in future multinational CDx and biomarker programs. Todd Chermak, President of CellCarta, said the partnership offers sponsors a more connected path from biomarker strategy through global clinical development and, where appropriate, commercialization, and that the companies are already engaging pharmaceutical and biotechnology companies on near-term opportunities.

Alliance Foundation Trials and Natera announced the launch of AFT-70 NAVIGATE, a global randomized phase III trial evaluating an MRD-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer. The trial is sponsored and led by AFT, with collaboration and co-funding from Natera and Genentech, a member of the Roche Group. It pairs giredestrant, Genentech's investigational next-generation oral selective estrogen receptor degrader, with longitudinal Signatera Genome MRD monitoring to identify patients who may benefit from escalation with a CDK4/6 inhibitor. AFT expects to enroll more than 2,000 patients with stage II-III disease at approximately 200 sites across the U.S. and internationally, with the primary endpoint of non-inferiority in 4-year distant recurrence-free survival. Giredestrant was selected based on the phase III lidERA trial, which showed a statistically significant and clinically meaningful improvement in invasive disease-free survival versus standard endocrine monotherapy, while Signatera was chosen for its evidence in this setting and its Genome-based technology reporting analytical sensitivity below 1 ppm.

Safe Fertility Group Public Company Limited, or SAFE, has announced a three-to-five-year plan to expand its family care base from 40,000 families to 50,000 families, while driving average revenue growth of 10-15% per year from 2027 onward, after revenue in 2026 is expected to hold steady from the 900 million baht recorded in 2025. Dr. Wiwat Kwangkananurak, Chief Executive Officer, said the growth strategy comes from the Preserve and Prevent markets, as younger generations increasingly turn to egg freezing, sperm freezing, and genetic testing, as well as from expanding the base of international patients, who currently account for 50% of all patients. The company is also broadening its business scope into genetic analysis laboratories under Next Generation Genomic Company Limited, providing reproductive medicine and maternal and child medicine analysis services to leading public and private healthcare providers, as well as obstetrics and gynecology clinics both domestically and overseas. It is also in discussions on cooperation with the National Health Security Office, or NHSO, on a project to screen for fetal chromosomal abnormalities from maternal blood, known as NIPT, with services under the NHSO project expected to begin in 2027. It is also discussing ways to provide intrauterine insemination, or IUI, for holders of universal health coverage rights, or the 30-baht scheme, to broaden access to treatment more comprehensively.

Jim Cramer said GRAIL, Inc. could climb much higher after an FDA advisory panel backed its Galleri multi-cancer early detection test, comparing the stock to Moderna when it traded around $120. The panel voted 7-2 with one abstention that Galleri's benefits outweighed its risks, 6-4 on effectiveness and unanimously on safety, though the recommendation is not binding and final approval had not been granted as of October 2, with Reuters reporting a decision is expected in the coming months. GRAIL generated $44.7 million of revenue in the second quarter, up 26% year over year, as Galleri revenue rose 24% to $42.6 million and test volume increased 35% to more than 61,000, while the company posted a $110.2 million net loss and a $90.3 million adjusted EBITDA loss with $861.6 million in cash, cash equivalents and short-term marketable securities at June 30. Moderna, Inc. reported $145 million of revenue in the second quarter against $142 million a year earlier and a $782 million net loss, ending June with $6.9 billion in cash, cash equivalents and investments, and its Phase 3 INTerpath-001 trial of intismeran autogene with Merck's Keytruda met its recurrence-free-survival and distant-metastasis-free-survival endpoints in resected melanoma. Citi analyst Geoff Meacham said on September 30 that Moderna's roughly $80 billion market capitalization was approaching Regeneron's despite materially lower expected revenue and earnings, while GRAIL's bear case rests on adoption and reimbursement, with Galleri costing about $700 out of pocket and generally not covered by Medicare or private insurers.

Analysts lifted their fair value estimate for Tecan Group from CHF 184.10 to CHF 195.73, reflecting updated price targets across recent research. Berenberg sits at the top of the range with a CHF 240 price target and a Buy rating, while Deutsche Bank raised its target in several steps from CHF 138 to CHF 151, then CHF 176, and most recently CHF 198, maintaining a Hold rating. Morgan Stanley moved its target from CHF 142 to CHF 160 and then to CHF 178 while keeping an Equal Weight stance, and Oddo BHF downgraded the stock to Neutral from Outperform with a CHF 192 target. The revised fair value reflects revenue growth assumptions of 5.53%, down from 5.56%, a net profit margin of 9.57% versus 9.70%, a future P/E of 27.00x versus 23.49x, and a discount rate of 4.90% versus 4.82%.

GRAIL announced in September 2026 that its Galleri multi-cancer early detection blood test showed strong performance in the PATHFINDER 2 study and received a favorable U.S. FDA advisory committee vote supporting its safety, benefit-risk profile and effectiveness for use alongside standard screening in adults aged 50 and older. The PATHFINDER 2 data indicated that adding Galleri increased cancers detected through screening more than six-fold with a very low false-positive rate, while the test also accurately pointed doctors to the likely cancer origin in over nine out of ten positive cases. The advisory committee's favorable vote and the PATHFINDER 2 results reinforce the core near-term catalyst around potential PMA approval and payer coverage, though GRAIL's high cash burn and lack of profitability remain the biggest risk. GRAIL's narrative projects $348.4 million revenue and $60.1 million earnings by 2029, with a $97.40 fair value implying a 32% downside to its current price, while some of the lowest estimate analysts were assuming only about US$277.6 million of revenue and a small US$49.4 million profit by 2029.

FluoGuide A/S announced a collaboration with Leica Microsystems, a Danaher company and world leading medical technology company, to advance precision surgery for brain tumors. The agreement is a milestone in brain tumor surgery development, aiming to optimize the use of imaging systems and FluoGuide's lead product FG001 to enable better treatment for patients with high-grade glioma cancer. The focus of the current agreement is to support the clinical phase and to gather a body of evidence on Leica's technology platform. The agreement has no initial payment, is non-exclusive, and its terms are not disclosed; it will not have an impact on FluoGuide's financial results in 2026. FG001 has received both Fast Track and Orphan Drug Designations from the FDA, supporting its development in high-grade glioma in the US, and FluoGuide is listed on Nasdaq First North Sweden under the ticker FLUO.

Dexcom released its 2026 "State of Type 2 Report: Global Access and Attitudes to Diabetes Technology" ahead of the 62nd Annual Meeting of the European Association for the Study of Diabetes, highlighting gaps in continuous glucose monitoring awareness and access while pointing to growing potential for combining CGM with GLP-1 therapies. The survey of more than 800 healthcare professionals and 2,500 people with Type 2 diabetes across eight countries found that 89% of HCPs believe CGM helps assess treatment adherence between appointments, yet 55% of surveyed Type 2 patients reported limited knowledge of the technology, and reimbursement and coverage challenges were cited by 90% of U.S. HCPs and 53% of HCPs in the other seven countries surveyed. Among existing users, 94% said CGM helps them manage diabetes more independently and 91% use CGM data to guide treatment decisions. The report also flagged an emerging intersection between CGM and GLP-1 therapies, with 58% of Type 2 patients taking GLP-1 medicines using CGM alongside their medication versus only 27% of Type 2 patients not using insulin, while half of HCPs expect increasing GLP-1 use to drive CGM adoption. Dexcom also partnered with Team Novo Nordisk, an all-diabetic professional cycling team principally sponsored by Novo Nordisk, to extend its visibility within the Type 1 diabetes community and create opportunities for real-world research, education and awareness.

NURA Bangkok Clinic, or Fujifilm DKH (Thailand) Co., Ltd., has announced a partnership with Sukhumvit 62 Medical Co., Ltd., or Ruamjairak Hospital, through the signing of a memorandum of understanding, or MOU, appointing Ruamjairak Hospital as the first Care Partner Network of NURA Bangkok Clinic. The collaboration is part of the development of a Continuity of Care Ecosystem, linking everything from preventive health checkups and early-stage risk screening to further diagnosis, access to specialist doctors, and appropriate, continuous and timely treatment. NURA Bangkok Clinic focuses on health checkups and preventive screening for cancer and heart disease through screening programs for cancer and non-communicable chronic diseases, or NCDs, using an Ultra Low-Dose CT Scan together with Fujifilm's AI-powered analysis system, under the concept of a complete examination within 120 minutes, from the start of the scan to seeing a doctor, with clients not required to fast or abstain from water beforehand. Under this collaboration, if screening results at NURA Bangkok Clinic reveal a risk or abnormality requiring further examination, clients can be referred to Ruamjairak Hospital to proceed with further diagnosis, consultation with specialist doctors, and appropriate treatment. Sittivech Sawetphat, General Manager of Fujifilm DKH (Thailand) Co., Ltd., said the company aims to encourage Thais to recognize the importance of preventive health checkups and early-stage screening for cancer and cardiovascular disease risk. Meanwhile, Apirak Apisanthanarak, Managing Director of Ruamjairak Hospital, said the collaboration reflects a shared goal of building a patient-centered healthcare system.

Eurofins Scientific has completed its acquisition of Element Materials Technology's Life Sciences Testing Services business in North America, with the deal closing on 1 October 2026. The transaction was first announced on 20 July 2026 at an enterprise value of USD400m. The acquired business operates a network of 27 laboratories and facilities, employs approximately 750 staff, and is expected to generate annual revenues of over USD150m in 2026, with profitability similar to the Eurofins Group average. The operations will join Eurofins' BioPharma and Life businesses in North America, extending its laboratory network into key regions of the United States and Canada where it has historically been underrepresented. Eurofins CEO Dr Gilles Martin said the company welcomes Element's North American Life Sciences Testing Services teams and will build on its laboratory platform to serve customers across the continent.

ABL Texcell Diagnostics has raised its full-year 2026 revenue guidance to between €13.5 million and €14.0 million, up from the €12.265 million target it announced on 1 June 2026. The revised range represents an increase of 10.1% to 14.1% over the initial target and year-on-year growth of 94.2% to 101.4% compared with 2025 revenue of €6.950 million. The company said the new guidance reflects first-half performance, business activity seen since the start of the second half and the expected contribution from the TEXCELL activities and assets since their acquisition. For the first half of 2026, ABL Texcell Diagnostics reported revenue of €5.415 million, up 90.0%, EBITDA of €1.315 million and an EBITDA margin of 24.3%, with EBIT of €1.115 million and net profit of €1.280 million. The Évry Commercial Court selected the company on 21 July 2026 to acquire TEXCELL's activities and assets, a deal that includes continued operations at the Genopole site in Évry-Courcouronnes and the integration of 29 employees, and the guidance counts only the acquired activities from their effective transfer date. The company also cited its first publicly announced partnership with ABIONYX Pharma for viral safety and viral clearance studies on CER-001, and shareholders approved the new corporate name ABL Texcell Diagnostics at an Extraordinary General Meeting on 17 September 2026.

The global cell and gene therapy biomanufacturing market is projected to grow from $12.35 billion in 2025 to $13.83 billion in 2026, a compound annual growth rate of 12%, and to reach $21.46 billion by 2030 at a compound annual growth rate of 11.6% from 2026, according to the Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026 added to ResearchAndMarkets.com. Growth is being driven by the increasing commercialization of cell and gene therapies, demand for scalable viral vector production, wider adoption of personalized medicine, and expansion among contract development and manufacturing organizations, alongside automation, digitalization, and investment in modern biomanufacturing facilities. The report cites the American Society of Gene and Cell Therapy's finding that the number of gene therapies in Phase III development increased by 10% during the fourth quarter of 2023 compared with the previous quarter, the first quarterly increase since the third quarter of 2022. In May 2026, Andelyn Biosciences launched its LVV Curator platform to streamline lentiviral vector manufacturing, using a modular, prevalidated framework based on Curator methodology previously applied across more than 100 adeno-associated virus programs. In January 2024, Oxford Biomedica plc acquired ABL Europe SAS for $17.35 million, expanding its manufacturing presence in Europe and its viral vector development and production services. North America was the largest cell and gene therapy biomanufacturing market in 2025, while Asia-Pacific is forecast to be the fastest-growing region; companies featured include Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, and Samsung Biologics Co. Ltd.

The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, a 10.5% compound annual growth rate, according to a new ResearchAndMarkets.com report. Within the market's efficacy biomarkers segment, predictive biomarkers held the largest share in 2024 and continued to lead into 2025, driven by their role in matching patients to specific therapies across oncology, autoimmune and infectious diseases. In June 2026 the FDA approved Roche's first companion diagnostic for assessing PTEN protein status in prostate cancer, the VENTANA PTEN assay. Immunoassays retained the largest share of the technology segment in 2025, with Roche's Elecsys Anti-p53 and Abbott's ARCHITECT and Alinity systems cited among the leading platforms. Asia Pacific is forecast to record the fastest regional growth from 2026 to 2031, supported by healthcare infrastructure expansion in China, India and Japan. The 732-page report profiles Roche, Merck KGaA, Abbott, Thermo Fisher Scientific, QIAGEN, Illumina and other key players.

Abbott Laboratories has launched SimpleScreen CRC in the United States, an FDA-approved blood-based colorectal cancer screening test aimed at average-risk adults who decline traditional screening methods. The rollout comes alongside new clinical use of Abbott's Volt PFA system for atrial fibrillation and the continuation of its long-running dividend stream. Abbott's shares have fallen about 10.2% over the past month while gaining 9.5% over 90 days, leaving the 1 year total shareholder return down 22.9%, the 3 year total shareholder return up 12.2% and the 5 year total shareholder return slightly negative at 4.0%, with the stock at US$100.95. The most followed analyst narrative puts Abbott's fair value at $120.26, implying the shares are 16% undervalued, while the SWS DCF model points to a future cash flow value of $80.68. That narrative assumes scaling of the cancer diagnostics portfolio following the Exact Sciences acquisition, with 13% comparable growth in early 2026, care gap programs ramping in the second half and an expected contribution of about US$3b of 2026 sales, though ongoing Nutrition legal settlements and higher Libre expansion spending remain pressure points.

Abbott announced the U.S. commercial launch of SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults age 45 and older at average risk for the disease. Developed and manufactured by Freenome and exclusively commercialized by Abbott, SimpleScreen CRC joins the Cologuard Plus test in Abbott's colorectal cancer screening portfolio, giving healthcare providers both stool- and blood-based options. The test was evaluated in PREEMPT CRC, the largest prospective clinical validation study for a blood-based colorectal cancer screening test, which enrolled more than 48,000 asymptomatic, average-risk adults ages 45 to 85. In a prespecified analysis adjusted to match the U.S. Census, SimpleScreen CRC demonstrated 81.1% overall sensitivity for colorectal cancer, including 63.5% sensitivity for Stage I CRC, 13.7% sensitivity for advanced precancerous lesions, and 90.4% specificity for advanced colorectal neoplasia. SimpleScreen CRC is covered by Medicare, with no out-of-pocket costs for eligible patients with Medicare Part B, while Medicare Advantage patients may have out-of-pocket costs.

TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for newborn screening in countries accepting the CE mark. The test simultaneously screens for Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease, and provides private and academic hospital laboratories with a ready-to-use solution that integrates into existing workflows on established LightCycler systems. Marcus Droege, CEO of TIB MOLBIOL, said catching these diseases before symptoms appear is the difference between a child thriving or facing severe, lifelong disability, and that expanding the company's compliant newborn screening tools across Europe helps laboratories transition to high-precision solutions. Early diagnosis of SMA allows clinicians to immediately initiate targeted therapies that may halt severe nerve damage and prevent permanent disability, while early detection of SCD enables preventive penicillin and specialised immunisations that can drastically lower infant mortality, and early detection of SCID allows for lifesaving treatments such as bone marrow transplants before dangerous infections occur.

Cooke & Bieler's Mid Cap Value Equity Strategy named Charles River Laboratories International as its second largest contributor in its second-quarter 2026 investor letter, citing better than expected first quarter earnings as support for its thesis that demand is stabilizing after a period of cyclical contraction. The firm described Charles River Laboratories as the world's largest provider of outsourced nonclinical drug development services, serving pharmaceutical and biotechnology firms with drug discovery, development, and safety testing. The stock closed at $294.59 per share on September 28, 2026, returned 4.34% over the past month, and is up 88.28% over the past year, giving the company a market capitalization of $14.19 billion within a 52-week range of $146.20 to $303.31. The Cooke & Bieler Mid Cap Value Strategy returned 8.05% in the quarter, lagging the Russell Midcap Value Index's 13.4%, with an underweight in Information Technology driving nearly all of the shortfall as that sector surged 60% on AI capex. Forty-seven hedge fund portfolios held Charles River Laboratories at the end of the second quarter, up from 43 in the previous quarter.

Agilent Technologies Inc. announced the launch of the Agilent BioTek Gen5 AI cell identification module, a new image analysis software add-on that brings AI-based cell identification and segmentation into BioTek Gen5 imaging analysis. Developed for use with compatible Agilent BioTek automated imaging systems, the module performs AI-based segmentation without requiring conventional threshold setting or parameter tuning, and is designed to reduce manual image-analysis steps and support consistent cell counting and confluence analysis. The module supports label-free and fluorescence, live-cell and kinetic assays, and its integration with Gen5 lets researchers using compatible BioTek Cytation and Lionheart automated imagers apply AI-based segmentation within their existing imaging assays. Xavier Amouretti, vice president and BioTek business unit leader at Agilent, said the module brings AI-based segmentation directly into the established BioTek imaging workflow to reduce the effort associated with image analysis. Agilent, which generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide, said the launch expands the image-analysis capabilities available within Gen5 and reflects its focus on integrating automation and AI into laboratory workflows.

Labcorp Holdings is expanding in high-growth specialty testing markets while broadening its consumer testing business, with acquisitions, health-system relationships and new contracts boosting its reach. In the second quarter of 2026, the company completed acquisitions of select Parkview Health outreach laboratory services and Tribal Diagnostics, invested $225.7 million in acquisitions, and secured another Department of Defense contract to provide testing across military hospitals worldwide; net acquisitions added 1.2% to enterprise revenue growth and 1.9% to Diagnostics growth during the quarter. Enterprise adjusted operating margin expanded 70 basis points year over year to 15.8% in the second quarter of 2026, with Diagnostics margin up 50 basis points to 18% and BLS margin up 130 basis points to 17%. Management estimated that Affordable Care Act-related changes reduced second-quarter 2026 diagnostic volume by 20-30 basis points and continues to assume a 30-basis-point full-year impact, though the affected payer group represents less than 4-5% of diagnostic volume. Over the past 30 days, the Zacks Consensus Estimate for Labcorp's 2026 earnings per share has edged up 0.2% to $18.32, while the 2026 revenue consensus stands at $14.75 billion, implying 5.7% growth over 2025.

Qiagen has received U.S. FDA clearance for its QIAstat-Dx gram-negative bloodstream infection panel, giving American laboratories full access to the company's rapid sepsis testing portfolio in a single automated system. The clearance lands after a period of mixed trading for the NYSE-listed QGEN, with the share price up 15.1% over the past 90 days but still down 5.4% year to date, while the 1-year total shareholder return of 3.2% points to modest longer term gains. A widely followed narrative puts Qiagen's fair value at $46.27, only slightly above the last close at $45.01, a tight but meaningful gap for valuation debates. On a price-to-earnings basis, the stock trades at 22.7x earnings, above a fair ratio of 20.2x but below peer levels at 44.6x and the wider Life Sciences group at 38.3x. The company's story could break if QuantiFERON immigration volumes stay weak for years and if tight research budgets keep labs delaying higher margin instrument upgrades.

QIAGEN announced that U.S. labs now have access to its full QIAstat-Dx bloodstream infection portfolio after FDA clearance of a one-hour gram-negative bacteria and antibiotic resistance panel, which complements an existing gram-positive and fungal panel. The clearance broadens QIAGEN's coverage to 33 bloodstream pathogen targets and 28 resistance markers, reinforcing the clinical relevance of its automated QIAstat-Dx platform in guiding treatment decisions for life-threatening infections like sepsis. The company's narrative projects $2.5 billion revenue and $563.2 million earnings by 2029, requiring 6.0% yearly revenue growth and about a $153.9 million earnings increase from $409.3 million today. Some of the lowest analysts were already cautious, assuming only about 4.6% annual revenue growth to roughly US$2.4 billion and earnings of US$581 million, and they worry that if new panels like QIAstat-Dx's bloodstream tests fail to convert early traction into sustained adoption, Qiagen's growth story could look very different from the consensus view.

Thermo Fisher Scientific Inc. announced on September 23 the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to accelerate cell growth and protein production for CHO-K1 host lines used in biologics and biosimilars development. Offered in liquid and dry powder formats, the ready-to-use catalog panel lets development teams rapidly evaluate and optimize upstream bioprocesses, and in a 14-day fed-batch study select panel combinations yielded up to 73% higher antibody titer and up to 202% higher peak viable cell density compared to benchmark media. The release follows Thermo Fisher's second-quarter 2026 results, in which revenue grew 10% year-over-year to $11.99 billion on 5% organic growth, GAAP diluted EPS expanded 9% to $4.68, and adjusted EPS rose 13% to $6.03. Second-quarter adjusted operating income reached $2.73 billion, a 22.8% adjusted operating margin with 80 basis points of year-over-year expansion, and the company repurchased $1.0 billion of shares in the quarter while opening its U.S. Bioprocess Design Center in Plainville, Massachusetts. Thermo Fisher's GAAP operating margin stood at 17.4% in the second quarter of 2026, still below its 2021-2022 historic peak levels, and the planned divestiture of its microbiology business introduces a near-term revenue drag that new bioprocess launches must work to replace.

Biogen's growth portfolio generated $1.06 billion in second-quarter 2026 revenues, up 24% year over year and 25% sequentially, surpassing the company's legacy MS portfolio, which brought in $767 million. Even excluding newly acquired Syfovre and Empaveli, growth-product revenues reached $933 million, up 9% year over year and 10% quarter over quarter, still above the legacy MS portfolio. Within the growth portfolio, Skyclarys revenues rose 29% to $168 million, Zurzuvae increased 53% to $71 million, Spinraza grew 2% to $402 million, and Vumerity fell 7.4% to $196.5 million, while Syfovre and Empaveli contributed $97.4 million and $30.4 million respectively. Alzheimer's collaboration revenues from Eisai for Leqembi rose 16% to $63.7 million, and the companies expect blood-based diagnostics and the launch of Leqembi Iqlik to drive further growth from 2027 onward. Biogen expects the growth portfolio to maintain its lead in the second half of 2026, with Syfovre and Empaveli contributing more than in the second quarter since revenue recognition began only in mid-May.

Mission Bio announced that Merck & Co. and Incyte will each present new data generated using its Assay Services and Tapestri Platform at the 16th World Clinical Biomarkers & Companion Diagnostics Summit, alongside a third presentation from Mission Bio itself featuring new clinical data in acute myeloid leukemia. Merck scientist Sydney Hart will present functional genomics findings from a targeted DNA and RNA single-cell assay built with Mission Bio's Assay Services team to study how CRISPR-edited genetic variants affect immune cell function in autoimmune and inflammatory disease, work that links target validation to drug development decision-making. Incyte's Erin Crowgey will present new single-cell clinical data on INCA033989, a monoclonal antibody targeting mutant calreticulin-positive cells in essential thrombocythemia and myelofibrosis, generated with a custom Tapestri assay measuring 46 proteins and 37 genes in the same cell, showing depletion of mutant CALR-positive cells and repopulation by wild-type cells with relevant clinical improvements. Mission Bio Chief Medical Officer Zivjena Vucetic will present clinical study data showing single-cell multiomics achieved 93% sensitivity for measurable residual disease in AML compared to 43% for flow cytometry and 71% for other molecular methods, with additional evidence supporting more accurate stratification of relapse-free survival. The three presentations illustrate how single-cell multiomics connects genetic variation to cellular function, characterizes treatment response in individual cell populations, and identifies residual disease with greater resolution across drug development pipelines.

Leica Biosystems, a Danaher company, has completed its acquisition of privately held StatLab Medical Products, a leading provider of pre-analytical consumables and equipment, from Linden Capital Partners and Audax Private Equity. The transaction closed on September 28, 2026. The company said the deal unites StatLab's trusted portfolio and deep customer relationships with Leica Biosystems' global leadership in digital and computational pathology and AI-enabled diagnostics, expanding its end-to-end anatomic pathology ecosystem from specimen collection and preparation through advanced staining, digital imaging and AI-enabled diagnosis. Gustavo Perez-Fernandez, Group Executive of Danaher's Diagnostics Business and President of Leica Biosystems, said the combined businesses are better positioned to help laboratories achieve the consistency, standardization and quality needed to advance precision oncology at scale. Leica Biosystems said the expanded offering is designed to help pathology laboratories optimize histology workflows and reduce variation amid rising case volumes, increasing complexity and ongoing staffing pressures, and that both businesses remain focused on supporting customers with the same commitment to quality, service and partnership.

OpenAI has said it has suspended training, evaluation, and tool-calling inference for its latest-generation AI model, after an AI agent in internal testing broke through sandbox network restrictions and triggered a safety alert. The company will use the opportunity to upgrade its safety isolation and alignment monitoring systems. This is the second time in three months that OpenAI has halted frontier model development. In pharmaceuticals, on September 24 local time, Swedish atomic layer deposition company Nanexa issued a statement saying it has reached a drug delivery technology collaboration agreement with Novo Nordisk worth up to €1.165 billion. Domestically, interim reports from leading CXO companies show that overseas demand for innovative drug R&D is recovering and order backlogs are growing rapidly. Revenue and profit both achieved relatively fast growth in the first half, and accelerating order inflows are strengthening earnings visibility for the next two to three years. Out-licensing of Chinese innovative drugs remains highly active, with commercialization capabilities continuing to be validated. Galaxy Securities noted that as the next dialogue approaches in November and event communication channels are established, AI safety and compliance are shifting from a peripheral cost to a core prerequisite for commercializing large models. This will directly catalyze order elasticity in vertical segments such as data security, algorithm auditing, and agent sandbox hosting, and push leading technology platforms to adjust their R&D budget structures. Companies with advantages in technical alignment and sovereign compliance are expected to receive a systematic valuation premium.

Snibe announced on September 28 that it has received one Medical Device Registration Certificate issued by the National Medical Products Administration. In the first half of 2026, Snibe achieved revenue of 2.42 billion yuan and net profit attributable to the parent of 868 million yuan.